Literature DB >> 9695185

CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.

S Sato1, J M Tuscano, M Inaoki, T F Tedder.   

Abstract

The CD22 cell-surface adhesion molecule is capable of modulating B lymphocyte antigen receptor (BCR)-mediated signals, as well as the generation of BCR-independent signals. Within the cytoplasmic domain of CD22 are motifs that are structurally homologous to known activation and inhibitory motifs. These motifs demonstrate physiologic significance via associations with known effector proteins that likely mediate their corresponding inhibitory and activation roles. Furthermore, the targeted deletion of CD22 in mice results in phenotypic changes and alterations in BCR-mediated signal transduction that are consistent with both positive and negative roles for CD22 in B cell development and activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9695185     DOI: 10.1006/smim.1998.0121

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  31 in total

1.  Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.

Authors:  Shui-On Leung; Kai Gao; Guang Yu Wang; Benny Ka-Wa Cheung; Kwan-Yeung Lee; Qi Zhao; Wing-Tai Cheung; Jun Zhi Wang
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling.

Authors:  Zilu Zhu; Ran Li; Hao Li; Tong Zhou; Randall S Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

Review 3.  Targeting B cells with biologics in systemic lupus erythematosus.

Authors:  Antonio La Cava
Journal:  Expert Opin Biol Ther       Date:  2010-10-04       Impact factor: 4.388

Review 4.  Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.

Authors:  Alisa B Lee-Sherick; Rachel M A Linger; Lia Gore; Amy K Keating; Douglas K Graham
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

Review 5.  Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future.

Authors:  Noam Jacob; William Stohl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

6.  CD21 signaling via C3 regulates Purkinje cell protein 4 expression.

Authors:  Amanda C Jacobson; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-02-07       Impact factor: 4.407

7.  Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.

Authors:  Bindu Varghese; Adam Widman; James Do; Behnaz Taidi; Debra K Czerwinski; John Timmerman; Shoshana Levy; Ronald Levy
Journal:  Blood       Date:  2009-09-17       Impact factor: 22.113

Review 8.  Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

Authors:  Manzurul A Sikder; Jonathan W Friedberg
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

9.  Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.

Authors:  Robert T O'Donnell; Yunpeng Ma; Hayes C McKnight; David Pearson; Joseph M Tuscano
Journal:  Cancer Immunol Immunother       Date:  2009-05-13       Impact factor: 6.968

10.  Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).

Authors:  Robert T O'Donnell; Shiloh M Martin; Yunpeng Ma; William C Zamboni; Joseph M Tuscano
Journal:  Invest New Drugs       Date:  2009-03-24       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.